Compare Adaptive Biotechnologies Corp (ADPT) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Verizon Communications Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.95 (market cap $4.04B), while Verizon Communications Inc trades at $46.9 (market cap $196.40B). The key difference: Verizon Communications Inc is far larger — about 48.6× Adaptive Biotechnologies Corp's market cap, and Verizon Communications Inc pays a 5.99% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | VZ | |
|---|---|---|
Market Cap | $4.04B | $196.40B |
Sector | Health | Media |
52-Week High | $25.45 | $51.38 |
52-Week Low | $12.30 | $38.40 |
Enterprise Value | $4.10B | $383.10B |
Volume | — | 22,584,735 |
Dividend Yield | — | 5.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Verizon (VZ) trades at $46.77, down 0.56% today, with a bullish technical signal from moving averages and a consensus analyst price target of $49.69. The company reported Q2 2026 EPS of $1.30, beating estimates, and maintains strong cash flow with $37.14B from operations in 2025. Recent news highlights partnerships, such as with Fi for pet tech integration, and network initiatives amid competitive pressures from SpaceX's Starlink.
Outlook: VZ offers value with a P/E of 12.31 and a 15.63% ROE, supported by stable dividends. Risks include rising debt to $298.5B in 2025 and revenue stagnation. Opportunities lie in fiber expansion and margin improvements, but investor caution is warranted due to competitive threats and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
